Altimmune, Inc. (NASDAQ:ALT) Receives $20.83 Average Price Target from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been given an average recommendation of “Buy” by the eight analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $20.83.

Several research analysts recently weighed in on ALT shares. UBS Group started coverage on shares of Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price for the company. Stifel Nicolaus assumed coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Altimmune in a research note on Wednesday.

Hedge Funds Weigh In On Altimmune

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. B. Riley Wealth Advisors Inc. increased its stake in Altimmune by 12.9% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock worth $144,000 after acquiring an additional 2,687 shares during the last quarter. Creative Planning grew its holdings in shares of Altimmune by 20.5% in the third quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after purchasing an additional 3,132 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after purchasing an additional 4,772 shares during the last quarter. Larson Financial Group LLC purchased a new stake in Altimmune during the third quarter valued at $31,000. Finally, The Manufacturers Life Insurance Company lifted its position in Altimmune by 30.7% during the second quarter. The Manufacturers Life Insurance Company now owns 26,973 shares of the company’s stock valued at $179,000 after purchasing an additional 6,339 shares during the last quarter. 78.05% of the stock is owned by institutional investors.

Altimmune Trading Up 5.3 %

Shares of NASDAQ:ALT opened at $6.99 on Friday. The stock has a 50 day moving average of $7.66 and a 200 day moving average of $7.17. The company has a market cap of $497.13 million, a PE ratio of -4.51 and a beta of 0.19. Altimmune has a 12-month low of $5.28 and a 12-month high of $14.84.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same quarter in the previous year, the company earned ($0.39) earnings per share. Equities research analysts predict that Altimmune will post -1.35 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.